Clinical trials: in Guinea
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Measles Infection
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children aged 1-15 either with or without…
- Trial name
- NCT06153979
- Testing
- Verorab
- Where
- 2 sites in Guinea, Mali
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mpox (Monkeypox), Monkeypox
Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea
This study has three primary objectives to address the public health challenges of the Mpox outbreak in Guinea, West Africa. Objective 1 (MOVIE-West Africa) focuses on understanding the kinetics of Monkeypox virus (MPXV)…
- Trial name
- MOVIE-TRACE-WA (NCT07534267)
- Where
- Guinea
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Acoziborole has been studied in an open-label pivotal Phase II/III trial (DNDi-OXA-02-HAT) in the DRC and Guinea. As the numbers of reported cases diminish, resources for surveillance and specialised screening will also taper.
- Conditions
- Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection, Sleeping Sickness
- Trial name
- OXA005 (NCT05433350)
- Testing
- Acoziborole
- Where
- 6 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 35 people
- Sponsor
- Drugs for Neglected Diseases
Childhood ALL
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in…
- Trial name
- LALGFA2019 (NCT04794296)
- Where
- 3 sites in Côte d’Ivoire, Guinea and 1 more
- Volunteers
- 500 people
- Sponsor
- French Africa Pediatric Oncology Group
Ebola Virus Disease
EBOla Post-Exposure Prophylaxis
EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
- Trial name
- EBO-PEP (NCT06841614)
- Testing
- Ervebo, Inmazeb
- Where
- 4 sites in Democratic Republic of the Congo, Guinea and 2 more
- Volunteers
- 160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, HIV-1-infection
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults…
- Conditions
- Tuberculosis, HIV-1-infection, Immuno-Deficiency
- Trial name
- DATURA (NCT04738812)
- Testing
- Intensified TB treatment (initial phase), WHO standard TB treatment (initial phase)
- Where
- 6 sites in Cambodia, Cameroon and 4 more
- Volunteers
- 1,330 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
Efficacy of Favipiravir Against Ebola (JIKI)
There is no specific treatment for Ebola Virus Disease (EVD). Current EVD care are supportive, and includes intravenous or oral rehydration, nutrition, pain killers, treatment of coinfections with antibacterial and antimalarial…
- Trial name
- JIKI (NCT02329054)
- Testing
- Favipiravir
- Where
- 4 sites in Guinea
- Volunteers
- 126 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the…
- Trial name
- DeTACT-Africa (NCT03923725)
- Testing
- Artemether-lumefantrine+ Amodiaquine (AL+AQ), Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Where
- 8 sites in Burkina Faso, Democratic Republic of the Congo and 6 more
- Volunteers
- 2,583 people
- Sponsor
- University of Oxford
Trypanosomiasis, African, Gambiense Trypanosomiasis
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
The goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Gambiense Trypanosomiasis, Sleeping Sickness
- Trial name
- OXA002 (NCT03087955)
- Testing
- Acoziborole
- Where
- 12 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 208 people
- Sponsor
- Drugs for Neglected Diseases
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Human African trypanosomiasis (HAT) or sleeping sickness is a tropical disease which is endemic in sub-Saharan Africa. Most cases of HAT are due to the parasite Trypanosoma brucei gambiense (T.b.
- Conditions
- Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection, Sleeping Sickness
- Trial name
- OXA004 (NCT05256017)
- Testing
- Acoziborole
- Where
- 7 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 1,208 people
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African, Sleeping Sickness
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
This study evaluates the effectiveness of fexinidazole administered to patients with human African trypanosomiasis due to T. b. gambiense (g-HAT) at all stages of the disease.
- Conditions
- Trypanosomiasis, African, Sleeping Sickness, Trypanosomiasis; Gambian
- Trial name
- NCT03025789
- Testing
- Fexinidazole
- Where
- 8 sites in Democratic Republic of the Congo, Guinea
- Volunteers
- 174 people
- Sponsor
- Drugs for Neglected Diseases
Malaria
Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea
Background: Half of the world s population is at risk of malaria. In 2015, there were 214 million cases of malaria and 438,000 deaths. A transmission-blocking vaccine (TBV) could help end the disease.
- Trial name
- NCT04969913
- Where
- 2 sites in United States, Guinea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Partnership for Research on Ebola VACcinations
The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults.
- Trial name
- PREVAC (NCT02876328)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, rVSVΔG-ZEBOV-GP
- Where
- 6 sites in Guinea, Liberia and 2 more
- Volunteers
- 4,789 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human African Trypanosomiasis, Sleeping Sickness
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
This study evaluates and compares the diagnostic specificity of 5 serological field tests for screening of the population at risk for human African trypanosomiasis due to Trypanosoma brucei gambiense.
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- SpeSerTryp (NCT05466630)
- Testing
- Serological field test for HAT, malaria rapid test, Immunologic laboratory tests
- Where
- 2 sites in Côte d’Ivoire, Guinea
- Volunteers
- 1,095 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Malaria
Malaria Prevalence Around Maferinyah, Guinea
Background: Many women in Sub-Saharan Africa get malaria while they are pregnant. Plasmodium falciparum is a parasite that can cause malaria. Placental malaria (PM) caused by P.
- Trial name
- NCT04105855
- Where
- Guinea
- Volunteers
- 3,392 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Febrile Illness
Febrile Illness in Guinea
To date, the underlying causes of community-acquired fever, particularly non-malarial fever, are insufficiently documented in Guinea.
- Trial name
- MuSIFe (NCT06122259)
- Where
- Guinea
- Volunteers
- 2,500 people
- Sponsor
- Centre National de Formation et de Recherche en Sante Rurale
Tuberculosis, Multidrug-Resistant
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin Resistant Tuberculosis (RR-TB) but only rifampicin…
- Trial name
- DIAMA (NCT03303963)
- Testing
- Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line, Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis
- Where
- 10 sites in Belgium, Benin and 8 more
- Volunteers
- 3,356 people
- Sponsor
- Dissou AFFOLABI
Cholera, Vibrio Cholerae Infection
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
- Trial name
- NCT05453253
- Testing
- Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
- Where
- Guinea
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Epicentre